Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2006; 12(30): 4794-4806
Published online Aug 14, 2006. doi: 10.3748/wjg.v12.i30.4794
Published online Aug 14, 2006. doi: 10.3748/wjg.v12.i30.4794
Drug | Infliximab |
Dosage | 5 mg/kg per infusion; usually started at wk 0, 2, and 6 and then repeated every 8 wk if necessary |
Indications | Chronically active disease, steroid-refractory and steroid-dependency, maintenance, fistulae |
Important side effects | Nausea, headache, abdominal pain, infections, sepsis; infusions reactions (early or delayed), reactivation of tuberculosis |
Monitoring | Vital signs around infusion |
Pregnancy | Unknown |
Comments | Exclude tuberculosis before infusions, consider concommittant use of imunosuppressants (azathioprine) to reduce antibody formation |
- Citation: Büning C, Lochs H. Conventional therapy for Crohn’s disease. World J Gastroenterol 2006; 12(30): 4794-4806
- URL: https://www.wjgnet.com/1007-9327/full/v12/i30/4794.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i30.4794